Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CRGX CARGO Therapeutics	$4.48 +0.4%	$4.45	$3.00 ▼ $25.45	$205.65M	0.3	1.79 million shs	985,283 shs
EDIT Editas Medicine	$2.49 -1.6%	$2.47	$0.91 ▼ $4.44	$211.79M	2.19	2.26 million shs	873,793 shs
LRMR Larimar Therapeutics	$3.66 -2.9%	$3.12	$1.61 ▼ $9.50	$241.38M	0.93	1.53 million shs	1.05 million shs
PYRGF PyroGenesis Canada	$0.28 -3.1%	$0.33	$0.25 ▼ $0.71	$52.56M	0.83	12,582 shs	68,535 shs

7 Energy Stocks to Buy and Hold Forever

With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CRGX CARGO Therapeutics	+0.45%	+0.22%	-2.18%	+11.44%	-67.63%
EDIT Editas Medicine	-1.58%	-0.80%	-12.94%	+71.72%	-39.42%
LRMR Larimar Therapeutics	-2.92%	+5.78%	+10.24%	+72.64%	-48.81%
PYRGF PyroGenesis Canada	-3.14%	-1.92%	-18.76%	-13.66%	-47.55%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
CRGX CARGO Therapeutics	2.5052 of 5 stars	2.9	0.0	0.0	3.4	1.7	1.3
EDIT Editas Medicine	4.2368 of 5 stars	3.2	3.0	4.3	3.2	2.5	0.6
LRMR Larimar Therapeutics	2.8736 of 5 stars	3.6	2.0	0.0	3.4	3.3	0.0
PYRGF PyroGenesis Canada	0.3452 of 5 stars	0.0	4.0	0.0	0.0	1.7	0.0

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
CRGX CARGO Therapeutics	1.86	Reduce	$15.40	243.75% Upside
EDIT Editas Medicine	2.31	Hold	$4.70	88.76% Upside
LRMR Larimar Therapeutics	3.11	Buy	$18.50	405.46% Upside
PYRGF PyroGenesis Canada	0.00	N/A	N/A	N/A

Current Analyst Ratings Breakdown

Latest PYRGF, EDIT, LRMR, and CRGX Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
7/8/2025	CRGX CARGO Therapeutics	Jefferies Financial Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Hold ➝ Hold	$3.70 ➝ $5.00
6/24/2025	LRMR Larimar Therapeutics	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy
6/24/2025	LRMR Larimar Therapeutics	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$17.00 ➝ $15.00
6/24/2025	LRMR Larimar Therapeutics	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$26.00
5/13/2025	EDIT Editas Medicine	Robert W. Baird Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$8.00 ➝ $4.00

(Data available from 8/8/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
CRGX CARGO Therapeutics	N/A	N/A	N/A	N/A	$7.83 per share	N/A
EDIT Editas Medicine	$32.31M	6.45	N/A	N/A	$1.63 per share	1.53
LRMR Larimar Therapeutics	N/A	N/A	N/A	N/A	$2.69 per share	N/A
PYRGF PyroGenesis Canada	$9.14M	5.75	N/A	N/A	($0.01) per share	-28.06

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
CRGX CARGO Therapeutics	-$167.50M	-$4.62	N/A	N/A	N/A	N/A	-45.93%	-39.58%	8/11/2025 (Estimated)
EDIT Editas Medicine	-$237.09M	-$3.04	N/A	N/A	N/A	-701.06%	-139.24%	-63.87%	N/A
LRMR Larimar Therapeutics	-$80.60M	-$1.49	N/A	N/A	N/A	N/A	-52.48%	-46.08%	N/A
PYRGF PyroGenesis Canada	-$21.12M	-$0.01	N/A	∞	N/A	-115.14%	N/A	-60.81%	N/A

Latest PYRGF, EDIT, LRMR, and CRGX Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue	Details
8/11/2025	Q2 2025	CRGX CARGO Therapeutics	-$0.42	N/A	N/A	N/A	N/A	N/A
5/12/2025	Q1 2025	EDIT Editas Medicine	-$0.51	-$0.43	+$0.08	-$0.92	$0.79 million	$4.66 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
CRGX CARGO Therapeutics	N/A	N/A	N/A	N/A	N/A
EDIT Editas Medicine	N/A	N/A	N/A	N/A	N/A
LRMR Larimar Therapeutics	N/A	N/A	N/A	N/A	N/A
PYRGF PyroGenesis Canada	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
CRGX CARGO Therapeutics	N/A	6.30	6.30
EDIT Editas Medicine	N/A	3.08	3.08
LRMR Larimar Therapeutics	N/A	7.48	7.48
PYRGF PyroGenesis Canada	N/A	0.60	0.50

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
CRGX CARGO Therapeutics	93.16%
EDIT Editas Medicine	71.90%
LRMR Larimar Therapeutics	91.92%
PYRGF PyroGenesis Canada	0.03%

Insider Ownership

Company	Insider Ownership
CRGX CARGO Therapeutics	2.92%
EDIT Editas Medicine	2.10%
LRMR Larimar Therapeutics	4.50%
PYRGF PyroGenesis Canada	47.68%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
CRGX CARGO Therapeutics	116	46.11 million	44.76 million	N/A
EDIT Editas Medicine	230	83.71 million	81.96 million	Optionable
LRMR Larimar Therapeutics	30	64.03 million	61.15 million	Optionable
PYRGF PyroGenesis Canada	90	187.31 million	96.34 million	No Data

PYRGF, EDIT, LRMR, and CRGX Headlines

Recent News About These Companies

PyroGenesis Announces Second Quarter 2025 Results

August 6 at 9:00 PM | globenewswire.com

PyroGenesis Signs Additional Contract with Constellium to Advance Aluminum Furnace Electrification Using Plasma Torch Technology

August 5 at 7:00 AM | globenewswire.com

PyroGenesis Canada (NASDAQ:PYRGF) Stock Price Down 1% - Here's What Happened

August 3, 2025 | marketbeat.com

PyroGenesis Schedules Second Quarter 2025 Financial Results and Business Update Conference Call

August 1, 2025 | globenewswire.com

PyroGenesis Receives Initial Contract for Titanium Metal Powder from European Additive Manufacturing Company

July 31, 2025 | globenewswire.com

PyroGenesis Confirms Third-Party SEM Analysis Supports Pilot-Scale Fumed Silica Morphology Consistent with Commercial-Grade Fumed Silica

July 28, 2025 | globenewswire.com

PyroGenesis Announces Completion of Coke-Oven Gas Valorization and Hydrogen Production Project for Tata Steel

July 15, 2025 | globenewswire.com

PyroGenesis Canada (NASDAQ:PYRGF) Stock Price Up 1.2% - Here's What Happened

July 10, 2025 | marketbeat.com

PyroGenesis Improves Fumed Silica Quality, Purity, and Consistency Across Multiple Production Cycles

July 8, 2025 | globenewswire.com

PyroGenesis Signs $600,000 Contract Targeting Plastic Waste Management Problem in Europe

July 2, 2025 | globenewswire.com

PyroGenesis Reports Voting Results from 2025 Annual Meeting of Shareholders - Morningstar

June 29, 2025 | morningstar.comM

PyroGenesis Reports Voting Results from 2025 Annual Meeting of Shareholders

June 27, 2025 | globenewswire.com

PyroGenesis Confirms Verification of Fumed Silica Samples by Leading Global Supplier

June 12, 2025 | globenewswire.com

PyroGenesis Announces Extension to Term of Warrants

June 9, 2025 | globenewswire.com

High-Tech Micro Cap Rallies After Securing Boeing Supplier Status

May 29, 2025 | msn.com

PyroGenesis Confirms Receiving Accelerated Customer Request for Fumed Silica Samples

May 28, 2025 | globenewswire.com

PyroGenesis Confirms Production of Fumed Silica at Pilot Scale Following Independent Analysis

May 21, 2025 | globenewswire.com

PyroGenesis Confirms Successful Collection of Material from Fumed Silica Pilot Plant Baghouse

May 15, 2025 | globenewswire.com

PyroGenesis, Inc. (PYRGF) Q1 2025 Earnings Call Transcript

May 14, 2025 | seekingalpha.com

PyroGenesis Announces First Quarter 2025 Results

May 13, 2025 | globenewswire.com

PyroGenesis Provides Update on Fumed Silica Project

May 13, 2025 | globenewswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

3 Short Squeeze Candidates With Big Catalysts on the Horizon
By Dan Schmidt | July 25, 2025
View 3 Short Squeeze Candidates With Big Catalysts on the Horizon
Why the American Eagle Stock Rally Isn't Just Speculation
By Gabriel Osorio-Mazilli | July 28, 2025
View Why the American Eagle Stock Rally Isn't Just Speculation
America Wants Drone Dominance: Are These Stocks Ready to Soar?
By Chris Markoch | July 20, 2025
View America Wants Drone Dominance: Are These Stocks Ready to Soar?
Super Micro Computer Sees Unusual Volume—Catalyst Ahead?
By Gabriel Osorio-Mazilli | July 25, 2025
View Super Micro Computer Sees Unusual Volume—Catalyst Ahead?
3 Bullish Biotech Stocks With Explosive Growth Trends
By Chris Markoch | July 21, 2025
View 3 Bullish Biotech Stocks With Explosive Growth Trends

PYRGF, EDIT, LRMR, and CRGX Company Descriptions

CARGO Therapeutics NASDAQ:CRGX

$4.48 +0.02 (+0.45%)

Closing price 08/7/2025 04:00 PM Eastern

Extended Trading

$4.50 +0.02 (+0.47%)

As of 06:30 AM Eastern

CARGO Therapeutics, Inc., a clinical-stage biotechnology company, develops chimeric antigen receptor (CAR) T-cell therapies for cancer patients. The company's lead program is CRG-022, an autologous CD22 CAR T-cell product candidate designed to address resistance mechanisms by targeting CD22, an alternate tumor antigen that is expressed in B-cell malignancies. It also develops CRG-023, a tri-specific CAR T product candidate that targets tumor cells with three B-cell antigen targets. The company was formerly known as Syncopation Life Sciences, Inc. and changed its name to CARGO Therapeutics, Inc. in September 2022. CARGO Therapeutics, Inc. was incorporated in 2019 and is headquartered in San Mateo, California.

Editas Medicine NASDAQ:EDIT

$2.49 -0.04 (-1.58%)

Closing price 08/7/2025 04:00 PM Eastern

Extended Trading

$2.53 +0.04 (+1.61%)

As of 08/7/2025 06:50 PM Eastern

Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. It develops a proprietary gene editing platform based on CRISPR technology. The company develops EDIT-101, which is in Phase 1/2 BRILLIANCE trial for Leber Congenital Amaurosis; and reni-cel, a clinical development gene-edited medicine to treat sickle cell disease and transfusion-dependent beta-thalassemia. In addition, the company is developing alpha-beta T cells for solid and liquid tumors; and gamma delta T cell therapies to treat cancer. It has a research collaboration with Juno Therapeutics, Inc. to develop engineered T cells for cancer; strategic alliance and option agreement with Allergan Pharmaceuticals International Limited. The company was formerly known as Gengine, Inc. and changed its name to Editas Medicine, Inc. in November 2013. Editas Medicine, Inc. was incorporated in 2013 and is based in Cambridge, Massachusetts.

Larimar Therapeutics NASDAQ:LRMR

$3.66 -0.11 (-2.92%)

Closing price 08/7/2025 04:00 PM Eastern

Extended Trading

$3.70 +0.03 (+0.96%)

As of 06:43 AM Eastern

Larimar Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing treatments for rare diseases using its novel cell penetrating peptide technology platform. Its lead product candidate is CTI-1601, which is in Phase 2 OLE clinical trial for the treatment of Friedreich's ataxia, a rare, progressive and fatal genetic disease. Larimar Therapeutics, Inc. is based in Bala Cynwyd, Pennsylvania.

PyroGenesis Canada NASDAQ:PYRGF

$0.28 -0.01 (-3.14%)

As of 08/7/2025 01:33 PM Eastern

PyroGenesis Canada Inc. designs, develops, manufactures, and commercializes plasma processes and solutions worldwide. The company offers DROSRITE, a process for enhancing metal recovery from dross without any hazardous by-products; plasma atomization process that allows produce and sell high purity spherical metal powders; PUREVAP, a process to produce high purity metallurgical and solar grade silicon from quartz; and PUREVAP NSiR, which is designed to transform silicon into spherical silicon nano powders and nanowires for use in lithium-ion batteries. It provides plasma torches and plasma torch systems used toreplace fossil fuel burners in industrial iron ore pelletization process; plasma arc waste destruction systems for waste destruction onboard ships; steam plasma arc refrigerant cracking systems for the destruction of certain refrigerants, including chlorofluorocarbons, hydrofluorocarbons, and hydrochlorofluorocarbons; plasma arc chemical warfare agent destruction systems, which are mobile platforms for the onsite destruction of chemical warfare agents; plasma resource recovery systems for land-based waste destruction and waste-to-energy applications; plasma torches for waste gasification and combustion; and plasma arc gasification and vitrification. In addition, it offers engineering and manufacturing expertise, and contract research, as well as turnkey process equipment packages to the defense, metallurgical, mining, additive manufacturing (including 3D printing), oil and gas, and environmental industries. Further, the company provides installation, commissioning, and start-up services. PyroGenesis Canada Inc. is headquartered in Montreal, Canada.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time